Yuanta Securities Korea noted on the 4th that the first clinical results of the non-small cell lung cancer treatment being developed by VORONOI are expected to be released sooner than anticipated and that the clinical trial is progressing rapidly. The investment recommendation is 'Buy,' with the target price raised by 50% from 160,000 won to 240,000 won. VORONOI's stock price on the previous trading day was 111,700 won.
VORONOI has decided to present the initial clinical data of the targeted therapy VRN11 for non-small cell lung cancer at the American Association for Cancer Research (AACR 2025) conference at the end of April.
Ha Hyun-soo, a researcher at Yuanta Securities Korea, said, 'It has been confirmed that the first clinical results of VRN11, which were expected to be disclosed at the American Society of Clinical Oncology (ASCO) at the end of May, will now be presented at the AACR held at the end of April,' and added, 'In addition to AACR, schedules for data presentations at multiple conferences such as WCLC and ESMO within the year have been announced, indicating that the clinical trials are progressing quickly.'
Regarding the 50% increase in the target price, Ha said, 'This reflects the value of VRN11 as a first-line treatment.' He added, 'The value of first-line treatment reflects only its potential for patients with central nervous system (CNS) metastasis, and given that the effectiveness of existing treatments has diminished in CNS metastasis, accelerated approval is likely to be possible.'
He further analyzed, 'VORONOI is expected to announce clinical results for various treatments including VRN11 and VRN07 starting with AACR this year, and positive data announcements are anticipated,' and stated, 'The release of clinical data is expected to be a strong momentum for stock price increases.'